|Study Description:||There are 5 parts to this clinical research study. MD Anderson will be |
taking part in Parts B, D, and F. This consent form will cover Parts B, D, and
The goal of Part B is to further test the highest tolerable dose of MK-3475
(pembrolizumab) that was found in Part A when given to patients with melanoma.
The safety of this drug will also be studied.
The goal of Part D is to study 2 dose levels of pembrolizumab when given to
patients with melanoma.
The goal of Part F is to study 2 dose levels of pembrolizumab when given to
patients with lung cancer.
Pembrolizumab is a drug that includes a protein naturally created by living
cells. It is designed to help the body's natural defense system react against
tumors by blocking proteins that cancers cells create to "turn off" the body's
immune (defense) system.